On August 31, EVEREST MED fell 5.19% in regular trading, trading at HK$33.0/share, with turnover of HK$108 million.

The decline extends the ongoing retreat in mRNA-concept stocks and broader biotech sector weakness. Previously catalyzed by Merck and Moderna's positive Phase 3 clinical results for their personalized mRNA cancer vaccine, EVEREST MED had rallied as much as 55% from August 20. Recent sessions have seen sustained profit-taking as earlier gains are unwound. Within the Biotechnology sector, peers were broadly under pressure, with AKESO down 4.67%, BEONE MEDICINES down 4.81%, 3SBIO down 4.36%, CANSINOBIO down 4.03%, and INNOVENT BIO down 3.72%.

On the fundamental side, EVEREST MED reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product TARPEYO saw sales growth of 94%. However, analysts have flagged risks including intensifying competition for TARPEYO and supply constraints for Xerava, while trimming revenue forecasts by 15%-18%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)